FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Danantara Eyes Stake in Indonesia Nickel Mine Project

By

Indonesia's sovereign wealth fund confirmed early-stage talks to buy Eramet's stake in the Weda Bay nickel project in the country, The Jakarta Globe reported Wednesday.

Danantara CEO Rosan Roeslani was also quoted in the report as saying that the fund is "open for talks" on investments and local partnerships in Indonesia.

PT Weda Bay Nickel is owned 51.3/37.8/10 by China's Tsingshan, French miner Eramet, and Indonesian state-owned PT Antam (IDX:ANTM), according to the joint venture's website.

Eramet did not immediately respond to a request for comment from.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Refex Industries Secures Supply Order Worth INR365 Million

Refex Industries (NSE:REFEX, BOM:532884) received an order worth 365 million Indian rupees from a Navratna public sector steel company for supply of bulk industrial commodity, according to a Wednesday filing.The order is to be executed within 40 days, the filing said.

$BOM:532884$NSE:REFEX
Asia

Zaggle Prepaid Ocean Services Names New Group CFO; Interim CFO to Step Down

Zaggle Prepaid Ocean Services (NSE:ZAGGLE, BOM:543985) appointed Venkatesh Ramachandran as group chief financial officer, effective May 18, according to a Wednesday filing on Indian bourses.Following the appointment, Rajesh Tummalaganti will cease to be interim CFO, effective May 17, the company said. He will continue as deputy chief financial officer, it added.

$BOM:543985$NSE:ZAGGLE
Asia

Smruthi Organics Clocks Sharp Decline in Fiscal Q4 Net Profit

Smruthi Organics' (BOM:540686) net profit more than halved to 10.7 million Indian rupees in the fiscal fourth quarter from 22.3 million rupees a year earlier, according to an Indian bourse filing on Wednesday.Earnings per share for the quarter ended March 31 contracted to 0.93 rupees from 1.95 rupees a year ago.The pharmaceutical company's revenue slipped year-on-year to 290.9 million rupees from 380.9 million rupees, the filing said.The company's board recommended a dividend of 1.5 rupees per share for fiscal 2026 ended March 31.Shares of the company were up 4% in after-market hours.

$BOM:540686